Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Mitchell R. Smith, MD PhD, Hailun Li, PhD, Fangxin Hong, PhD, Leo I. Gordon, MD, Randy D. Gascoyne, Elisabeth Paietta, MD, Ranjana H Advani, MD, Andres Forrero-Torres, Sandra J Horning, MD, Brad S. Kahl, MD

Blood (2015) 126 (23): 2702.

https://doi.org/10.1182/blood.V126.23.2702.2702

Published: 2015

Journal Articles

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Gilles Salles, MDPhD, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H.J. van Oers, MD PhD, Catherine Fortpied, Msc, Ruth Pettengell, MD, Peter Dreger, MD, Mathias Witzens-Harig, MD, Umberto Vitolo, MD, Andrea Evangelista, Maria Gomes da Silva, Hailun Li, Laurence Freedman, PhD, Thomas M Habermann, MD, Ofer Shpilberg, MD

Blood (2014) 124 (21): 4462.

https://doi.org/10.1182/blood.V124.21.4462.4462

Published: 2014

Journal Articles

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Julie E. Chang, Hailun Li, Mitchell R. Smith, Randy D. Gascoyne, Elisabeth M. Paietta, David T. Yang, Ranjana H. Advani, Sandra J. Horning, Brad S. Kahl

Blood (2014) 123 (11): 1665–1673.

https://doi.org/10.1182/blood-2013-08-523845

Published: 2014

Includes: Supplemental data

Journal Articles

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Jennifer A. Kanakry, Meir Shamay, Yvette L. Kasamon, Hailun Li, MS, Randy D. Gascoyne, MD, Leo I. Gordon, MD, Ariela Noy, MD, Ethel Cesarman, MD, PhD, Jeannette Y Lee, Ph.D., Sandra J. Horning, MD, Richard F. Ambinder

Blood (2013) 122 (21): 4232.

https://doi.org/10.1182/blood.V122.21.4232.4232

Published: 2013

Journal Articles

Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lymphome d’Adultes

Ranjana H. Advani, MD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Hailun Li, MS, Brad S. Kahl, MD, Vicki A. Morrison, MD, Edie A. Weller, PhD, Gaurav Varma, MSPH, Richard I Fisher, MD, Bruce A. Peterson, MD, Bruce D. Cheson, M.D., Randy D. Gascoyne, MD, Sandra J. Horning, MD, Sami Bousetta, Bertrand Coiffier, MD, PhD, Marita Ziepert, Michael Pfreundschuh, MD

Blood (2013) 122 (21): 3045.

https://doi.org/10.1182/blood.V122.21.3045.3045

Published: 2013

Journal Articles

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Blood (2013) 122 (21): 4277.

https://doi.org/10.1182/blood.V122.21.4277.4277

Published: 2013

Journal Articles

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Jennifer A. Kanakry, Hailun Li, Lan L. Gellert, M. Victor Lemas, Wen-son Hsieh, Fangxin Hong, King L. Tan, Randy D. Gascoyne, Leo I. Gordon, Richard I. Fisher, Nancy L. Bartlett, Patrick Stiff, Bruce D. Cheson, Ranjana Advani, Thomas P. Miller, Brad S. Kahl, Sandra J. Horning, Richard F. Ambinder

Blood (2013) 121 (18): 3547–3553.

https://doi.org/10.1182/blood-2012-09-454694

Published: 2013

Includes: Supplemental data

Journal Articles

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Brad S. Kahl, M.D., Hailun Li, MS, Mitchell R Smith, MD, PhD, Randy D. Gascoyne, MD, David T. Yang, MD, Elisabeth Paietta, PhD, Ranjana H. Advani, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 153.

https://doi.org/10.1182/blood.V120.21.153.153

Published: 2012

Journal Articles

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Lode J. Swinnen, Hailun Li, MS, Andrew Quon, MD, Randy D. Gascoyne, MD, Erik A. Ranheim, MD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 687.

https://doi.org/10.1182/blood.V120.21.687.687

Published: 2012

Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 4779.

https://doi.org/10.1182/blood.V120.21.4779.4779

Published: 2012

Journal Articles

Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Ranjana H. Advani, MD, Fangxin Hong, PhD, Hailun Li, MS, Brad S. Kahl, MD, Michael Pfreundschuh, Marita Ziepert

Blood (2011) 118 (21): 1568.

https://doi.org/10.1182/blood.V118.21.1568.1568

Published: 2011

Journal Articles

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

Brad S Kahl, MD, Hailun Li, Ph.D., Mitchell R Smith, MD, PhD, Randy D. Gascoyne, MD, Elisabeth Paietta, MD, Ranjana Advani, MD, Sandra J Horning, MD

Blood (2009) 114 (22): 1661.

https://doi.org/10.1182/blood.V114.22.1661.1661

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only